Efficacy of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

This randomized clinical trial reports the final overall survival results of ivosidenib (AG-120)—a first-in-class, oral, small-molecule inhibitor of mutant IDH1—vs placebo for patients with unresectable or metastatic cholangiocarcinoma with with IDH1 mutation.

Read the full article here

Related Articles